About Fitzsimons Innovation Community
Innovation is happening. Right here.
Fitzsimons Innovation Community is a sprawling campus of leading-edge laboratory workspace where innovative health and life sciences companies of all sizes take their research to the next level to cure diseases, save lives, and improve care.
Smart, inclusive, forward-thinking, and highly educated people lead life sciences innovation in Colorado, the Hub for Health Impact. Together, we welcome life sciences organizations looking to call Colorado home and to collaborate with a robust community already in on the secret: the health and life sciences industry in Colorado is strong and making a global impact on the future of health.
Move in, and build your vision here—today.
The emphasis is on Community
We called it a community for a reason. From the board of directors to the newest company on campus, everyone at Fitzsimons Innovation Community knows that easy access to collaboration has direct results on success. From idea incubation to final-product manufacturing, your end-to-end innovation can come alive right here on our campus. All that Colorado sunshine is just a bonus.
Community
Cutting-edge discoveries in action
Capital Raised
Last year, Fitzsimons Innovation Community member companies attracted more than $72M in investments to support R&D, prepare for clinical trials, accelerate commercialization, retain or recruit talent, and expand to new markets.
Companies Fundraising
Fitzsimons Innovation Community member companies are actively involved in fundraising to power their progress.
Companies Launching New Products
Fitzsimons Innovation Community member companies are launching new products and solutions to market.
*Fitzsimons Innovation Community Member Growth Survey responses (January – December 2024)
A blueprint for the next chapter of scientific development
The new Fitzsiomons Innovation Community Master Plan has been decades in the making, evolving with changing technology, people, and infrastructure and designed to meet the work-live-play needs of the modern life sciences professional. Explore our vision for the future.
Our team is on
your team
You know best when it comes to your projects, and we know how to keep you up and running with first-class scientific facilities management and community engagement. Our priority is to help you thrive on this campus and we have the proven tools and expertise to make that happen.
Backed by excellence
Our Board of Directors is a group of leaders who are passionate about your goals and discoveries. Armed with serious business, legislative, and health sciences credentials, they know winning innovation inside and out, and they put our Community and its members at the heart of every strategic decision.
FIC to confirm if we have an image from recent Board of Directors meeting (or can obtain one)
Meet our Community members
From early-stage founders to seasoned physicians and researchers, our Community brings together diverse talent united by a mission to transform the future of patient care. Explore our directory to connect with the people and expertise shaping life sciences innovation at Fitzsimons Innovation Community.
Fitzsimons Innovation Community News
Kelly Brough Shares Community’s Bold Vision on Visit Aurora Podcast
Fitzsimons Innovation Community President & CEO Kelly Brough was recently featured on Visit Aurora, Colorado’s The Gateway to the Rockies Podcast where she shared the bold vision behind the newly approved master plan and how the Fitzsimons campus is transforming into Aurora’s first true urban district. From cutting-edge research that’s reshaping patient care to green…National Trial: Ketamine Raises Heart Risk, No Survival Advantage Over Etomidate in Emergency Intubation
CU Anschutz researchers help lead the largest U.S. randomized trial highlighting ketamine’s cardiovascular risks while guiding emergency and critical care practice.New Study Finds Cystic Fibrosis Drug Allows Patients to Safely Scale Back Lung Therapies
A new multi-site study led by researchers at CU Anschutz shows that people with cystic fibrosis (CF) who start the triple-drug therapy elexacaftor/tezacaftor/ivacaftor (ETI) can safely reduce many of their daily lung treatments while maintaining good health for years.From Lab to Clinic: CU Anschutz Launches Phase 1 Clinical Trial of Promising Combination Therapy for Resistant Ovarian Cancer
A first-of-its-kind combination therapy could make treatment more effective by attacking hard-to-treat cancer from two angles.
